US COVID-19 Vaccines and Therapeutics Tracker—Market Insights and Trends, H1 2021

US COVID-19 Vaccines and Therapeutics Tracker—Market Insights and Trends, H1 2021

Agnostic Vaccine Platform Technology Enhancing Future Growth Potential of Participants in the Value Chain

RELEASE DATE
30-Apr-2021
REGION
North America
Research Code: K613-01-00-00-00
SKU: HC03412-NA-TC_25410

$2,450.00

Special Price $2,205.00 save 10 %

In stock
SKU
HC03412-NA-TC_25410

$2,450.00

$2,205.00 save 10 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This study by Frost & Sullivan’s Healthcare and Life Sciences team provides critical insights into the US COVID-19 vaccines and therapeutics market, including developing vaccines, supply chain considerations, and requirements to manage distribution. The study also identifies actionable and profitable growth opportunities for industry participants. The US response to the pandemic has been disorganized and made worse with the politicization of vaccine approval and distribution, creating distrust and delaying the country’s vaccination program. Each state in the US has its own vaccination strategy and as such, state health department websites are critical sources of information on when, where, and how to get vaccines.

As of 31 March 2021, the US Food & Drug Administration granted Emergency Use Authorization to three vaccines manufactured respectively by Pfizer and BioNTech, Moderna, and Johnson & Johnson. Novavax and AstraZeneca vaccines are two other leading vaccine candidates expected to be approved for use in Q2 2021. Apart from vaccines, drugs are likely to play a critical role in treating individuals not responding to vaccines, not receiving vaccines, and who still contracted the virus despite vaccination.

Maintaining vaccine integrity through all stages of the supply chain requires never-before-seen levels of monitoring and coordination among stakeholders. Partnerships between input supply firms and distributors are as critical as collaborations between vaccine sponsors and contract manufacturers to scale up production for mass immunization. Key topics covered in the study include:
•     Key COVID-19 vaccines and therapeutics analysis
•     COVID-19 vaccines supply chain and distribution analysis
•     Snapshot of the US vaccination strategy
•     Prospective analysis of COVID-19 becoming endemic

Author: Surbhi Gupta

Table of Contents

Growth Opportunities Fuel the Growth Pipeline Engine™

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top Three Strategic Imperatives on the US COVID-19 Vaccines and Therapeutics Market

H1 2021 US Key Tracking Metrics

Executive Summary

Executive Summary (continued)

COVID-19 Vaccines Snapshot—Pipeline Analysis

COVID-19 Vaccines Snapshot—Vaccines Granted EUA

COVID-19 Vaccines Snapshot—Key Manufacturing Deals and Partnerships for the US Supply of Approved Vaccines

COVID-19 Vaccines Snapshot—Key Vaccine Candidates in Phase III

COVID-19 Therapeutics Snapshot—Current Global Treatments

COVID-19 Therapeutics Snapshot—Key Small Molecules in Phase III

COVID-19 Therapeutics Snapshot—Key mAbs in Phase III

COVID-19 Vaccines Manufacturing Supply Chain—Stages and Inputs

COVID-19 Vaccines Supply Chain—US Key Stakeholders

COVID-19 Vaccines Supply Chain from Factory to the Point of Use

US COVID-19 Vaccines Distribution Framework

Logistics Providers—Maintaining the Cold Chain to the Point of Use

Logistics Providers—Key Activities of Operation Warp Speed’s Logistics Partners

Central Distribution Hub—McKesson’s Role in Vaccines Distribution

Ancillary Supply Kits—Requisites for Different COVID-19 Vaccines

Scaling Up Syringes and Needles Manufacturing to Meet Vaccination Targets

US COVID-19 Vaccination Snapshot—By Vaccine Type

US COVID-19 Vaccination Snapshot—Administration Sites

US COVID-19 Vaccines Distribution Sites—Private Companies Fortifying Distribution Networks

US COVID-19 Vaccination Snapshot—Rollout in Key States

US COVID-19 Vaccination Snapshot—Successful Rollout Examples

Possible Factors of COVID-19 Becoming Endemic

Future of COVID-19 Vaccination—Seasonal Rollout Possibility

Growth Opportunity 1—Agnostic Vaccine Platform Technology for Emerging Virus Variants and Future Infectious Disease Outbreaks, 2021

Growth Opportunity 1—Agnostic Vaccine Platform Technology for Emerging Virus Variants and Future Infectious Disease Outbreaks, 2021 (continued)

Key Companies—Developing Next-generation COVID-19 Vaccines

Growth Opportunity 2—Precise Syringes and Adequate Dry Ice Supply for Effective Mass Vaccination, 2021

Growth Opportunity 2—Precise Syringes and Adequate Dry Ice Supply for Effective Mass Vaccination, 2021 (continued)

List of Exhibits

List of Exhibits (continued)

Legal Disclaimer

Related Research
This study by Frost & Sullivans Healthcare and Life Sciences team provides critical insights into the US COVID-19 vaccines and therapeutics market, including developing vaccines, supply chain considerations, and requirements to manage distribution. The study also identifies actionable and profitable growth opportunities for industry participants. The US response to the pandemic has been disorganized and made worse with the politicization of vaccine approval and distribution, creating distrust and delaying the countrys vaccination program. Each state in the US has its own vaccination strategy and as such, state health department websites are critical sources of information on when, where, and how to get vaccines. As of 31 March 2021, the US Food & Drug Administration granted Emergency Use Authorization to three vaccines manufactured respectively by Pfizer and BioNTech, Moderna, and Johnson & Johnson. Novavax and AstraZeneca vaccines are two other leading vaccine candidates expected to be approved for use in Q2 2021. Apart from vaccines, drugs are likely to play a critical role in treating individuals not responding to vaccines, not receiving vaccines, and who still contracted the virus despite vaccination. Maintaining vaccine integrity through all stages of the supply chain requires never-before-seen levels of monitoring and coordination among stakeholders. Partnerships between input supply firms and distributors are as critical as collaborations between vaccine sponsors and contract manufacturers to scale up production for mass immunization. Key topics covered in the study include: • Key COVID-19 vaccines and therapeutics analysis • COVID-19 vaccines supply chain and distribution analysis • Snapshot of the US vaccination strategy • Prospective analysis of COVID-19 becoming endemic Author: Surbhi Gupta
More Information
No Index No
Podcast No
Author Surbhi Gupta
Industries Healthcare
WIP Number K613-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9562-B1,9568-B1,9611-B1,9627-B1